文献速递血脂与心血管预防

PCSK9抑制与动脉粥样硬化性心血管疾病预防:现实与宣传是否匹配?

PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
PubMed 文献 · Heart · 2017-06-08

本综述评估PCSK9抑制用于预防动脉粥样硬化性心血管疾病的潜力是否与宣传热度相符。evolocumab和alirocumab两种全人源单克隆抗体已获许可,可使低密度脂蛋白胆固醇降低超过50%,安全性一般与安慰剂相当。FOURIER试验显示稳定心血管疾病患者2年内显著减少心血管事件,ODYSSEY OUTCOMES试验预计2018年报告急性冠脉综合征后人群的心血管结局数据。

要点

  • evolocumab和alirocumab可使低密度脂蛋白胆固醇降低超过50%,安全性一般与安慰剂相当。
  • bococizumab因出现中和抗体随时间降低疗效而提前终止开发。
  • FOURIER试验显示稳定心血管疾病患者2年内心血管事件显著减少。

核心结论

  • PCSK9抑制的潜力是否匹配宣传热度尚待进一步结局试验验证,合适的患者选择将是关键,需考虑这些疗法较高的药物成本。

研究设计与样本

  • 本综述评估PCSK9抑制用于预防动脉粥样硬化性心血管疾病的潜力是否与宣传热度相符。

主要发现

  • evolocumab和alirocumab是两种全人源单克隆抗体,已在美国和欧盟获许可用于临床,可使低密度脂蛋白胆固醇降低超过50%,安全性一般与安慰剂相当。
  • 第三种人源化单克隆抗体bococizumab的开发项目因出现中和抗体随时间降低疗效而提前终止。
  • FOURIER是首个心血管结局试验,显示稳定心血管疾病患者2年内心血管事件显著减少。
  • ODYSSEY OUTCOMES试验比较alirocumab与安慰剂,预计2018年报告急性冠脉综合征后人群的心血管结局数据。
  • II期ORION-1研究使用inclisiran(一种针对PCSK9的小干扰RNA),提示两剂inclisiran在9个月内产生LDL胆固醇时间平均降低50%。

关键数值与推荐

  • evolocumab和alirocumab可使低密度脂蛋白胆固醇降低超过50%。
  • 单克隆抗体每年需注射12-26次。
  • inclisiran每年注射两次,ORION-4心血管结局试验将评估其心血管获益。

临床怎么用

  • 鉴于这些疗法较高的药物成本,合适的患者选择将是关键。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Within this review we look at whether the potential provided by proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition for prevention of atherosclerotic cardiovascular disease matches the excitement generated. Two fully human monoclonal antibodies to PCSK9 are currently licenced for clinical use both in the USA and the European Union: evolocumab and alirocumab. These reduce low-density lipoprotein cholesterol by over 50% across a range of populations and were generally found to have a safety profile comparable with placebo. The development programme for a third humanised monoclonal antibody, bococizumab, was terminated early due to the presence of neutralising antibodies reducing its efficacy over time. Results from the first cardiovascular outcomes trial, FOURIER, have demonstrated significant reductions in cardiovascular events in a population with stable cardiovascular disease over a 2-year period. The ODYSSEY OUTCOMES trial comparing alirocumab to placebo is expected to report in 2018 and provide cardiovascular outcome data in a post acute coronary syndrome population. Monoclonal antibodies have an injection burden of 12-26 injections per year. An alternative approach to reducing PCSK9 is to inhibit translation of the messenger RNA for PCSK9. The phase II ORION-1 study using inclisiran, a small interference RNA to PCSK9, suggested that two doses of inclisiran produced time averaged reductions in LDL cholesterol of 50% over 9 months. The ORION-4 cardiovascular outcome trial will assess the cardiovascular benefits of two injections per year using inclisiran. With further outcome trials expected, appropriate patient selection will be key considering the higher drug costs of these therapies.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Hadjiphilippou S, Ray KK. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? Heart. 2017. PMID: 28596304. doi:10.1136/heartjnl-2016-310844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。